fda approves semaglutide Oral as First GLP-1 Pill for Weight Loss FDA approves once-weekly semaglutide for

The number of lawsuits against GLP-1 drugmakers has now reached 1,443

Tirzepatide and Metabolic Research Researchers investigating tirzepatide focus on: Obesity research Weight management pathways Glycemic control Appetite signaling Endocrine receptor activity Energy expenditure Glucose metabolism Published phase 2 and phase 3 trial research involving tirzepatide demonstrated substantial reductions in body weight and metabolic improvements in adults with obesity and type 2 diabetes

WiLD Norway and The Life Science Cluster invite you to an in-depth evening exploring why GLP-1 biology matters specifically for women, and why it deserves far more attention in research, clinical practice, and leadership conversations

Did you know that the invention of GLP-1 drugs came out of federally-funded research on lizard venom